【摘要】 目的:评估安罗替尼在小细胞肺癌(small-cell lung cancer,SCLC)三线及以上治疗中的疗效及安全性。方法:选取2018年6月至2019年6月本院收治的SCLC三线及以上治疗的患者31例,口服安罗替尼12 mg/d,服用2周停1周,6周后开始评价疗效,对比治疗前后PS评分及血清肿瘤标志物NSE水平变化情况和不良反应发生情况。结果:31例患者中,部分缓解率为9.7%(3/31),疾病稳定率为80.6%(25/31),疾病进展率为9.7%(3/31),客观缓解率为9.7%(3/31),疾病控制率为90.3%(28/31)。治疗后,患者PS评分低于治疗前,但差异无统计学意义(P>0.05);血清肿瘤标志物NSE水平显著低于治疗前,差异具有统计学意义(P<0.05)。常见的药物相关不良反应发生率为:食欲下降28例(90.3%);乏力25例(80.6%);高血压15例(48.4%);蛋白尿12例(38.7%);口腔炎10例(32.3%);咯血8例(25.8%);声音嘶哑6例(19.4%);中性粒细胞下降6例(19.4%);贫血6例(19.4%);甲减6例(19.4%);手足综合征4例(12.9%);肝功能异常4例(12.9%)。结论:安罗替尼在小细胞肺癌(SCLC)三线及以上治疗中疗效好,可降低肿瘤标志物NSE水平,延长患者的生存期,且该药的不良反应大部分为Ⅰ-Ⅱ级,耐受性良好。更多还原

【Abstract】 Objective:To evaluate the effect and safety of anlotinib in the treatment of the patients with small-cell lung cancer(SCLC) for third-line and above.Methods:31 patients with third line and above for SCLC in this hospital from June 2018 to June 2019 were selected and orally took anlotinib 12 mg/d for two weeks,then stopped for one week.The curative effect began to be was evaluated after 6 weeks.PS score and serum NSE before and after treatment were compared and the adverse reactions of SCLC patients during the treatment were observed.Results:Among 31 patients,the partial remission rate in patients was 9.7%(3/31).The disease stabilization rate was 80.6%(25/31). The disease progression rate was 9. 7%( 3/31). The objective remission rate was 9. 7%( 3/31) and the disease control rate was 90. 3%( 28/31). The PS score of patients after anlotinib was lower than the PS score before anlotinib,but the differences were not statistically significant( P > 0. 05). The serum NSE after anlotinib was lower than before anlotinib,and the differences were statistically significant( P < 0. 05). The incidence rates of common drug-related adverse reactions were 90. 3% for loss of appetite,80. 6% for fatigue,48. 4% for hypertension,38. 7% for proteinuria,32. 3% for stomatitis,25. 8% for hemoptysis,19. 4% for hoarseness,19. 4% for neutropenia,19. 4% for anemia,19. 4% for hyporhyroidism,12. 9% for hand-foot syndrome,12. 9% for abnormal liver function. Conclusion:Anlotinib has a good effect in treating SCLC for third-line and above,can reduce the serum NSE of patients and extend the survival period of the patient,moreover the majority of drug adverse reactions are the grade Ⅰ-Ⅱ and the tolerance is good.更多还原